SAN FRANCISCO–(BUSINESS WIRE)–Miroculus, Inc., a developer of revolutionary tools for personal laboratory automation, today announced the appointment of Mark Lewis to Executive Chairman. Mark has been a board member at Miroculus since October 2018.
“We are pleased to announce Mark’s new role as Executive Chairman at Miroculus. In addition to his broader board role, Mark will also work closely with our leadership team on the commercialization of the recently launched Miro Canvas™ and the development of future generations of our microfluidic platforms,” said Alejandro Tocigl, CEO of Miroculus. “His extensive experience in the development and commercialization of integrated instrument platforms and his proven leadership skills at leading organizations such as Illumina and Becton Dickinson will help fulfill our mission of advancing science and improving people’s lives faster.”
“I look forward to working with the talented, dedicated team at Miroculus as we continue to advance solutions that enable researchers and clinicians to deploy even the most complex next-generation sequencing protocols in their labs,” said Mark Lewis, Executive Chairman of Miroculus. “This is a particularly exciting time for Miroculus with the recent launch of the Miro Canvas, ideal for supporting Long Read Next Generation Sequencing (NGS) platforms, rapid whole genome sequencing and hybrid capture applications, among others suitable. Miroculus continues to innovate in the field of microfluidics with menu enhancements and more fundamental technological improvements that we expect to implement in future products. NGS is our primary focus, but we are actively exploring opportunities to apply our technologies to other life sciences workflows,” said Lewis.
Mark has over 45 years of experience in the life sciences industry, developing and commercializing genotyping, DNA sequencing, molecular biology and high content screening platforms and technologies. Previously, he served as interim CEO of Swift Biosciences, an NGS library prep provider, in 2017 and 2018 and served as a board member from 2017 until Danaher acquired the company in 2021. Mark has also held several leadership positions at Illumina, including senior vice president of product development, where he led the development of the HiSeq™ and MiSeq™ Next generation sequencing platforms. Mark is also a board member of AEENA Dx, Inc., a non-invasive cancer diagnostics company, and an advisor to UC San Diego as a member of the Dean’s Leadership Council for Biological Sciences.
About Miroculus, Inc.
Miroculus develops revolutionary tools for personal laboratory automation. Our technology offers industry-leading assay flexibility and automation capacity in an affordable digital microfluidics platform that enables seamless workflow integration for both established and novel molecular protocols. For more information visit us at www.miroculus.com, @miroculus or LinkedIn.